Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Nivolumab Versus Everolimus in Patients With Advanced Renal Cell Carcinoma: Updated Results With Long-Term Follow-Up of the Randomized, Open-Label, Phase 3 CheckMate 025 TrialCancer 2020 Jul 16;[EPub Ahead of Print], RJ Motzer, B Escudier, S George, HJ Hammers, S Srinivas, SS Tykodi, JA Sosman, ER Plimack, G Procopio, DF McDermott, D Castellano, TK Choueiri, F Donskov, H Gurney, S Oudard, M Richardet, K Peltola, AS Alva, M Carducci, J Wagstaff, C Chevreau, S Fukasawa, Y Tomita, TC Gauler, CK Kollmannsberger, FA Schutz, J Larkin, D Cella, MB McHenry, SS Saggi, NM Tannir
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.